Primary immune thrombocytopenia is a B-cell-mediated autoimmune disorder in which autoantibodies attack platelet glycoproteins such as GPIIb/IIIa, GPIb/IX, and GPV. This causes immune-mediated destruction of platelets and impaired formation of new platelets. The disease is manifested by a bleeding tendency of varying severity and often debilitating fatigue. Most patients respond to corticosteroids, immunosuppressants, thrombopoietin receptor agonists, or SYK inhibitors. In 10-15% of cases, these are multi-refractory forms, with an increased risk of bleeding and a significant decrease in the quality of life. The BCMA-CD3 T-cell adapter is proposed as a salvage therapy for these multirefractory cases.